Joshua H. Bilenker, President & CEO at Loxo Oncology, Inc. (LOXO), sold 12,952 shares at $160.61 ($2.1M) on 2018-10-04, disclosed to the SEC on 2018-10-05.
Open-market sale of $2.1M LOXO by President & CEO. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $160.61 | 1,700 | $273K | 13.0% |
| 2 | $161.41 | 1,553 | $251K | 11.9% |
| 3 | $162.60 | 3,152 | $513K | 24.3% |
| 4 | $162.60 | 3,152 | $513K | 24.3% |
| 5 | $163.64 | 2,000 | $327K | 15.5% |
| 6 | $164.59 | 1,395 |
| $230K |
| 10.9% |
| Total | $162.57 avg | 12,952 | $2.1M | 100% |
| Filing → |
| LOXO | SELL | 2018-12-12 | $2.7M | — | Filing → |
| LOXO | SELL | 2018-12-12 | $1.0M | — | Filing → |
| LOXO | SELL | 2018-11-28 | $1.2M | — | Filing → |